WASHINGTON -- The FDA approved another thrombopoietin receptor agonist on Monday, for an indication not covered by other drugs intended to raise platelet counts. The new agent is avatrombopag ...

The US Food and Drug Administration (FDA) has approved avatrombopag (Doptelet, AkaRx Inc) to increase platelet counts in adults with thrombocytopenia and chronic liver disease who are to undergo a ...

To provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in ...

Doptelet (avatrombopag) is used to increase platelet count in certain situations. The typical dosage is 1 to 3 oral tablets taken once daily. Your specific dosage depends on factors such as your ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

A new study found that most routine laboratory tests are not reliable for diagnosing long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Anna Sjöström at the research group ...